To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
BioFocus and Usher III Initiative, Inc. Announce Collaboration
Read time: Less than a minute
BioFocus and the Usher III Initiative, Inc., a not-for-profit organization, announced that they have embarked on a drug discovery project focused on Usher Syndrome Type III.
Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.
“We are pleased to support the Usher III Initiative in its aim to find a targeted treatment and cure for Usher III,” said Angus MacLeod, Vice President, Medicinal Chemistry, BioFocus. “This collaboration will utilize BioFocus’ expertise in integrated drug discovery programs.”
Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.
“We are pleased to support the Usher III Initiative in its aim to find a targeted treatment and cure for Usher III,” said Angus MacLeod, Vice President, Medicinal Chemistry, BioFocus. “This collaboration will utilize BioFocus’ expertise in integrated drug discovery programs.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
